CellCo
CellCo develops cell-selective siRNA delivery platforms that target disease-driving proteins at their source, enabling treatment of traditionally undruggable targets. Their CellOS and CellFlow system combines AI-guided glycan decoding, proteome screening, and experimental validation to design ligands for immune, kidney, CNS, and lung cells, focusing on chronic inflammatory and age-related diseases.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
- Artificial Intelligence
Funding
Founders
Founder details are not available yet.
Product
Problem
Many disease-driving proteins are considered "undruggable" with conventional small molecules or biologics, leaving chronic inflammatory and age-related conditions without effective treatments. Existing delivery methods for siRNA often lack cell selectivity, causing off-target effects in healthy cells and limiting therapeutic potential.
Solution
CellCo provides a cell-selective siRNA delivery platform that reduces disease-driving proteins at their source, opening access to previously undruggable targets. The platform, CellOS + CellFlow, systematically decodes glycans using AI and molecular dynamics proteome screening, paired with synthesis and experimental validation. CellOS screens over 400 protein families to rank candidates for selectivity, while CellFlow handles synthesis, structural analytics, binding, and cell and in vivo studies. This integrated loop enables the design of ligands targeting immune cells, kidney, CNS, and lungs, with a therapeutic focus on inflammaging—chronic inflammatory and age-related diseases.
Target Audience
Primary customers are biopharmaceutical companies and research institutions developing therapies for chronic inflammatory and age-related diseases, particularly those targeting undruggable proteins.
Features
- AI+MD proteome screening across a theoretical glycan space of 10^21+ combinations
- CellOS screens +400 protein families, ranking candidates for cell-type selectivity
- CellFlow integrates synthesis, structural analytics, binding assays, and in vivo validation
- Ligand candidates targeting immune cells, kidney, CNS, lungs, and more
- Pipeline focused on shared mechanisms across metabolic/liver, fibrotic organ, cardiorenal/vascular, and neuro-immune diseases